Osemozotan

Summary

Osemozotan (CHEMBL1742408) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Chemistry: 343.4 Da · C19H21NO5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742408
Name	Osemozotan
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	198747
Molecular formula	C19H21NO5
Molecular weight	343.4
InChIKey	MEEQBDCQPIZMLY-HNNXBMFYSA-N

SMILES: C1[C@@H](OC2=CC=CC=C2O1)CNCCCOC3=CC4=C(C=C3)OCO4

IUPAC name: 3-(1,3-benzodioxol-5-yloxy)-N-[[(3S)-2,3-dihydro-1,4-benzodioxin-3-yl]methyl]propan-1-amine

Also known as: Mkc-242, MN-305, Osemozotan, OSEMOZOTAN, osemozotan

Patent coverage: 90 distinct patent families (245 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 161 (66%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).